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Background: Considering that depressive and anxiety symptoms are common in schizophrenia, this study investigated
whether the severity of a psychotic episode in an acute phase schizophrenia cohort is predictive of concurrent
depressive and anxiety features.
Method: Fifty one recently hospitalised patients suffering from acute phase schizophrenia participated prospectively in a
cross-sectional study. The severity of the psychotic episode, the depressive features and the anxiety features were
measured by the Structured Clinical Interview for Positive and Negative Syndrome Scale (SCI-PANSS), the Calgary
Depression Scale for Schizophrenia (CDSS), the Hamilton Anxiety Rating Scale (HAM-A) and the Staden Schizophrenia
Anxiety Rating Scale (S-SARS). The total SCI-PANSS-scores were adjusted to exclude appropriately the depression or
anxiety items contained therein. To examine akathisia as potential confounder, the Barnes Akathisia Scale was also
applied. The relationships were examined using linear regressions and paired t-tests were performed between
lower and higher scores on the SCI-PANSS.
Results: A higher adjusted total SCI-PANSS-score predicted statistically significantly higher scores for depressive
features on the CDSS (p < 0.0001) and for anxiety features on the HAM-A (p = 0.05) and the S-SARS (p < 0.0001).
The group that scored more or equal to the median (=99) of the adjusted total SCI-PANSS, scored significantly
higher (p < 0.0001) on the CDSS, the HAM-A and the S-SARS than the group scoring below it. Akathisia measured
distinctly different (p < 0.0001) from both the anxiety measures.
Conclusion: The study suggests that the severity of a psychotic episode in acute phase schizophrenia predicts
the severity of concurrent depressive and anxiety features respectively.
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Although not defining features of schizophrenia, depres-
sive and anxiety features present commonly in patients
suffering from schizophrenia [1]. The lifetime prevalence
of depression in patients with schizophrenia is reported
to be 60 to 80% [2-5]. This suggests a significant risk
when compared with a lifetime prevalence of depres-
sion of 8–26% in the general population [6]. For anxiety
disorders, a meta-analysis by Achim et al. found a
pooled prevalence rate of 38.3% in schizophrenia with* Correspondence: werdie.vanstaden@up.ac.za
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unless otherwise stated.a 95%-confidence interval of 26.3% to 50.4%, which
seems also higher than the 28.8% reported for the general
population [7,8].
A rather complex relationship between schizophrenia
symptoms and features of depression had already been
the interest of Bleuler, among others, at the beginning of
the 20th century. Bleuler described the relationship as
follows: “the special position of depressive mood swings in
schizophrenia varies from case to case and in some cases
seems to be triggered by the schizophrenic disease process,
and in others takes the role of secondary symptoms…” [9].
Congruently, another study found differential prevalence
rates of 52% in acutely psychotic patients and 38% during
more stable periods of the disease [10].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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are limited to the post-psychotic period has been chal-
lenged by many studies that have established that de-
pressive features are also present during the acute
psychotic phase of the illness [10-12]. Hirsch et al. sug-
gest that the highest rate of depression in patients with
schizophrenia is found during the acute episode [13]. At
time of admission to hospital, half of the acutely ill
psychotic patients with schizophrenia present with sig-
nificant depressive features. Some of these patients ex-
perience a spontaneous remission of the features within
3 weeks, while about half develop persistent depressive
features. Another study found a remission rate of even
98% as the psychosis remitted [12].
Concurrent depressive features in schizophrenia pa-
tients are associated with increased morbidity and
mortality [14]. In this cohort study of 7217 patients in
Finland conducted over a 17 year period, it was shown
that accompanying depressive features in schizophrenia
incur elevated risks for both natural and unnatural mor-
tality [14]. Suicide was one of the leading causes of pre-
mature death among these patients, and was related to
the severity of depressive features. Also in another study,
depressive features accounted for nearly 50% of the sui-
cidal intent seen in a sample of 267 patients between the
ages of 18 and 70 [15].
Depressive features are associated, furthermore, with
an increased rate of relapse, more frequent and longer
duration of hospital admissions and a poor response to
pharmacological treatments [2]. Cognitive impairment,
substance abuse, poor social functioning, and suicide or
suicide attempts have also been reported [5,16]. Neuro-
psychological impairments seen in schizophrenia, espe-
cially of memory and attention, have also been linked
with depressive features [16]. The relationship between
schizophrenia and anxiety features is also complex as
suggested by the variable prevalence figures for the re-
spective anxiety disorders [7]. Statistically significant het-
erogeneity among prevalence figures was found, spanning
all kinds of anxiety disorders. As with the severity of de-
pressive features, the severity of anxiety is also of clinical
significance. Anxiety disorders on their own can adversely
affect quality of life, mobility, education, employment, so-
cial functioning, health care, and physical well-being [17].
Patients with both schizophrenia and anxiety features suf-
fer from more global functional impairment as well as
more severe limitations in the domains of employment
and social life – suggesting that anxiety features in these
patients bring about an additional burden to their already
compromised quality of life [18].
Social anxiety disorder in schizophrenia is associated
with a higher lifetime rate of suicide attempts, greater le-
thality of suicide attempts, more past substance/alcohol
abuse disorder, lower social adjustment, and overall qualityof life [19]. In a study by Mazeh et al., which investi-
gated the prevalence and correlates of social anxiety
disorder in patients with schizophrenia, significant cor-
relation was found between the score of the Liebowitz
Social Anxiety Scale and the positive symptom subscale
of the PANSS, which highlights the complex interaction
between anxiety and schizophrenia [20]. Comorbid panic
attacks in schizophrenia are associated with depressive
features and have a negative impact on quality of life
when compared to healthy controls in all domains of the
World Health Organization Quality of Life Instrument
[21]. Also in a longitudinal study, anxiety disorders were
found to be the best predictor of subjective quality of life
in patients with schizophrenia [22].
The relationship of schizophrenia with depressive and
anxiety features respectively needs to be investigated fur-
ther, considering the clinical importance and prevalence
of these in schizophrenia. Considering that this relation-
ship may be different in the acute psychotic phase com-
pared to the post-psychotic phase, this study investigated
a cohort of patients during the acute phase of schizo-
phrenia for concurrent depressive and anxiety features.
More specifically, it enquired for the first time as far
as we could establish, whether the severity of a psychotic
episode is predictive of concurrent depressive and anxiety




Fifty one patients between the ages of 18 to 65 who were
suffering from an acute phase of schizophrenia were
prospectively included within ten days of their admission
to the Weskoppies Psychiatric Hospital in Pretoria, South
Africa. For inclusion, they met the DSM-IV-TR criteria for
schizophrenia [23], and the acute phase was verified by a
minimum total score requirement of 60 on the Structured
Clinical Interview for Positive and Negative Syndrome
Scale (SCI-PANSS) as well as a score of at least 4 on any 2
of the SCI-PANSS items that constitute a psychotic item
subscale (these are, hallucinatory behaviour, delusions, con-
ceptual disorganisation, and suspiciousness).
Patients were excluded if they suffered from another
psychiatric diagnosis in addition to schizophrenia; a neuro-
logical condition affecting the central nervous system; sub-
stance dependence; or who were likely to suffer from
substance withdrawal symptoms. Patients with schizoaffec-
tive disorder were excluded by applying the C-criterion of
DSM-IV diagnostic criteria for schizoaffective disorder, viz.
that symptoms that meet criteria for a mood episode are
present for a substantial portion of the total duration of
the active and residual periods of the illness. In addition,
patients with a history of taking benzodiazepines regularly
during the past month were excluded as well as patients
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prior to applying the measures of this study.
Measures
The Structured Clinical Interview for Positive and Nega-
tive Syndrome Scale (SCI-PANSS) was used to measure
the severity of the psychotic episode [24]. Since this scale
contains specifically an item for depression and one for
anxiety, each of these were excluded from the total SCI-
PANSS score and are reported here as two adjusted total
scores (that is, a total SCI-PANSS score minus respect-
ively the depression and anxiety items).
Depressive features were measured by the Calgary De-
pression Scale for Schizophrenia that was developed specif-
ically for schizophrenia patients [25]. It is an observer rated
scale that consists of 9 items, each with 4 anchor points.
Anxiety was measured by two observer rated scales: the
Hamilton Anxiety Rating Scale (HAM-A), which has 14
items, each of which is rated from 0 (none) to 4 (severe,
grossly disabling) [26]. It is not specifically designed for the
schizophrenia population and marks mostly bodily and
behavioural manifestations of anxiety; In addition, the
Staden Schizophrenia Anxiety Rating Scale (S-SARS) was
used, consisting of 10 items, each with 6 narrative anchor
points descriptive of severity. The items are persecutory
and nihilistic anxiety; perceptual anxiety; anxiety attacks;
situational anxiety; obsessive-compulsive anxiety; somatic
anxiety; psychomotor and cognitive anxiety; worry and
fear; control-related anxiety, and impairment from anxiety.
To distinguish anxiety from akathisia, an extrapyram-
idal side effect of commonly used medication for this
group of patients [11], the Barnes Akathisia Scale was
used. It is an observer rated scale consisting of 4 items
with 6 anchor points each [27].
Descriptive variables included age, gender, medica-
tion used during the past week, depot medication during
the past month, and the number of previous hospital
admissions.
Statistical analyses
Means and standard deviations on the total scores
(continuous variables) obtained in the administration of
the respective measurement instruments were calculated.
Statistical testing was done by means of linear regression.
As an alternative statistical strategy, the median of the ad-
justed total SCI-PANSS-scores was used to demarcate
lower and higher scores, on which paired t-tests (upper
sided) were performed. The paired t-test (two-sided) was
also performed between the measure of akathisia and the
respective anxiety measures.
Ethical provisions
The Faculty of Health Sciences Research Ethics Committee
of the University of Pretoria provided ethics approval forthe study and the hospital’s chief executive officer provided
the necessary permission. All participants gave written in-
formed consent after they had been clinically assessed as
being capable of doing so [28,29]. Patients who were not
capable of consenting were excluded from the study. The
study was executed in compliance with the Declaration of
Helsinki (2008).
Results
Demographic, hospitalisation and medication
characteristics of participants
Fifty one patients were recruited in this study with a mean
age of 37.02 years (SD = 13.29). Thirty nine subjects were
male (76.47%) and 12 were female (23.53%). The mean
number of previous admissions was 4.06 (SD = 2.55). All of
the participants had been hospitalised at psychiatric units
previously. Seven had been admitted once before (13.73%),
and 13 had been admitted at least 3 times before (25.49%).
Twenty nine patients (56.86%) used one oral antipsychotic
medication, whereas 6 (11.76%) used none. A third of pa-
tients (n = 17) were on a depot antipsychotic medication.
Symptom characteristics of participants
Participants experienced severe psychotic features as
suggested by a mean total SCI-PANSS score of 97.61
(SD = 17.83), ranging from 60 to 146. The mean on the
positive symptoms subscale was 26.18 (SD = 4.87), ranging
between 10 and 34. The negative symptoms subscale
scored a mean of 24.2 (SD = 5.8), ranging between 12 and
39. The general psychopathology subscale scores ranged
between 26 and 77 with a mean of 47.12 (SD = 10.84).
Regarding depressive features, 7.6% of participants
scored zero on all items of the Calgary Depression
Scale for Schizophrenia. The mean total score was 6.45
(SD = 5.50; ranging to 21). Thirteen of the participants had
suicidal ideation of which 6 (11.8%) were considered to be
severely suicidal, having scored maximum on the suicide
rating item of the scale.
Regarding anxiety features, 3 participants (5.88%) scored
zero on all items of the Hamilton Anxiety scale. The mean
score was 11.29 (SD = 6.68), ranging from one to 27. The
scores on the S-SARS ranged from zero to 42, with a
mean of 18.88 (SD = 10.13). The specific anxiety subscale,
with items on persecutory and nihilistic anxiety, per-
ceptual anxiety, anxiety attacks, situational anxiety and
obsessive-compulsive anxiety, yielded a mean of 8.80
(SD = 5.51; range 0 – 23). The general anxiety subscale,
with items on somatic anxiety, psychomotor and cognitive
agitation, worry and fear, control-related anxiety and im-
pairment from anxiety yielded a mean of 10.08 (SD = 5.12;
range 0 – 19).
Eighteen participants (35.3%) had no features of akathisia
according to the Barnes Akathisia Scale. The mean score
was low at 1.67 (SD = 1.96) ranging from 0 to 9.
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respectively, depressive and anxiety features
A higher adjusted total SCI-PANSS-score (i.e., the total
SCI-PANSS-score minus the depression item) predicted
statistically highly significantly a higher score on the
Calgary Depression Scale for Schizophrenia (CDSS) (see
linear regression results in Table 1). Moreover, the group
that scored more or equal to the median (with the me-
dian being 99) of the total SCI-PANSS, scored signifi-
cantly higher on the CDSS than the group below this
median (see the paired t-test figures in Table 1).
Similarly for anxiety: the linear regression analyses
yielded statistically significant results for the adjusted total
SCI-PANSS-score (i.e., total SCI-PANSS-score minus the
anxiety item) predicting higher scores on, respectively, the
Hamilton Anxiety Scale (HAM-A) and the Staden Schizo-
phrenia Anxiety Rating Scale (S-SARS). Comparing the
group that scored higher or equal to the median of the
total SCI-PANSS-score to the lower scoring group, yielded
statistically highly significant predictions of higher scores
on the HAM-A and the S-SARS (see Table 1). Statistically
highly significant results were also found for the subscales
of the S-SARS.
To explore more about the details contained within
the total scores, the sub-scores were also examined al-
beit rather tentatively considering the modest sample
size. For the SCI-PANSS-subscales, viz. the Positive Syn-
drome Subscale; the Negative Syndrome Subscale; and
the General Psychopathology Subscale, linear regressions
were performed to ascertain the contributions of the
SCI-PANSS-subscales to the predicative relationships
with respectively the CDSS, the HAM-A, the S-SARS
and the subscales of the S-SARS. The results are presented
in Table 2, showing that higher scores on respectively
the General Psychopathology Subscale (as appropriately
adjusted) and the Negative Syndrome Subscale predicted
higher values (statistically highly significantly) for the
CDSS, S-SARS and the subscales of the S-SARS. How-
ever, a similar relationship between the scores of the
Negative Syndrome Subscale and the HAM-A did notTable 1 Total SCI-PANSS predicting CDSS, HAM-A-and S-SARS
Measures Linea
F-valu
SCI-PANSS without depression item CDSS 27.73
SCI-PANSS without anxiety item HAM-A 4.18
SCI-PANSS without anxiety item S-SARS (total) 31.05
SCI-PANSS without anxiety item General Anxiety Subscale
of S-SARS
29.14
SCI-PANSS without anxiety item Specific Anxiety Subscale
of S-SARS
24.51
*= statistically significant. **= statistically highly significant.emerge. Results did not support scores of the Positive
Syndrome Subscale predicting the scores of the CDSS,
but approached statistical significance for predicting the
scores on the measures of anxiety (except for the General
Anxiety Subscale of the S-SARS that yielded statistically
significant values).
The concern that akathisia as an adverse effect of anti-
psychotic medication may appear like anxiety in examining
the relationships as reported above, was not sustained by
the results. The measure of akathisia measured distinctly
from the anxiety measures. Statistically highly significant
differences between the Barnes Akathisia Scale and the
measures of anxiety were found: these are, for the HAM-A
(mean difference = 9.63; 95% CI = 7.76 to 11.49; t = 10.37;
p < 0.0001) and for the S-SARS (mean difference = 17.22;
95% CI = 14.54 to 19.89; t = 12.92; p < 0.0001). The total
Barnes scores neither proved to be a statistically significant
covariant to the adjusted total SCI-PANSS predicting
respectively the HAM-A (F = 0.01; p = 0.93) and S-SARS
(F = 0.07; p = 0.8).
The measurements of depressive features on the CDSS
in this cohort were found to be statistically highly signifi-
cantly different from anxiety features as measured by the
HAM-A (mean difference = 4.84; 95% CI = 3.0 to 6.69;
t = 5.27; p < 0.0001) and the S-SARS (mean difference =
12.43; 95% CI = 10.24 to 14.63; t = 11.37; p < 0.0001).
Similarly, the measurements on the adjusted SCI-PANSS
were found to be statistically highly significantly differ-
ent from the CDSS (mean difference = 87.88; 95% CI =
83.88 to 91.88; t = 44.12; p < 0.0001), the HAM-A (mean
difference = 83.0; 95% CI = 78.35 to 87.65; t = 35.88;
p < 0.0001), and the S-SARS (mean difference = 75.41; 95%
CI = 71.65 to 79.18; t = 40.23; p < 0.0001).
Discussion
The main finding of this study is that the severity of a
psychotic episode in acute phase schizophrenia predicts
the severity of concurrent depressive and anxiety fea-
tures respectively. Whereas most of the previous studies






< 0.0001** 88.55 87.26 to infinity 114.97 < 0.0001**
0.05* 83.71 82.14 to infinity 89.50 < 0.0001**
< 0.0001** 76.12 73.74 to infinity 53.68 < 0.0001**
< 0.0001** 84.92 83.72 to infinity 118.50 < 0.0001**
< 0.0001** 86.20 84.90 to infinity 111.72 < 0.0001**




SCI-PANSS Positive Syndrome Subscale
CDSS 7.93 0.39
HAM-A 3.73 0.06
Total S-SARS 3.52 0.07
S-SARS General Anxiety Subscale 4.28 0.04*
S-SARS Specific Anxiety Subscale 2.24 0.14
SCI-PANSS Negative Syndrome Subscale
CDSS 23.64 < 0.0001**
HAM-A 0.84 0.44
Total S-SARS 11.61 0.001**
S-SARS General Anxiety Subscale 11.34 0.001**
S-SARS Specific Anxiety Subscale 9.43 0.004**
SCI-PANSS General Psychopathology
Subscale minus depression item
CDSS 27.02 < 0.0001**
SCI-PANSS General Psychopathology
Subscale minus anxiety item
HAM-A 4.07 0.05*
Total S-SARS 37.13 < 0.0001**
S-SARS General Anxiety Subscale 31.83 < 0.0001**
S-SARS Specific Anxiety Subscale 31.20 < 0.0001**
*= statistically significant. **= statistically highly significant.
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ings as far as we could establish for the first time in a
cohort that suffered on average from a rather severe de-
gree of psychotic episode. This study, moreover, measured
anxiety in its various presentations without assuming that
anxiety in acute phase schizophrenia necessarily present
in the form of established diagnostic categories of anxiety
disorders.
The results statistically differentiated anxiety from
akathisia in this cohort, suggesting that akathisia is not a
confounder in the finding that more severe anxiety is pre-
dicted by how severe the psychotic episode is. The finding
that the severity of a psychotic episode in acute phase
schizophrenia predicts the severity of concurrent depres-
sive and anxiety features is further supported by the verifi-
cation that the severity measurements in this study of the
psychotic episode, the depressive features and the anxiety
features are distinct. That indicates that the main finding
of this study is not an artefact of overlap between the re-
spective measure instruments. That also suggests that
the instruments validly distinguished between clusters of
respectively psychotic, depressive and anxiety features,
notwithstanding the practical difficulties in distinguish-
ing between specific symptoms of these kinds reportedelsewhere (e.g., intrusive and repetitive delusional ideas vs.
obsessions in obsessive compulsive disorder; hallucinatory
experiences vs. flashbacks in post-traumatic stress disorder;
delusional ideas of reference vs. fear of being judge in so-
cial anxiety disorder) [7,30].
One should be cautious about generalising the find-
ings, however. That lesser severity of a psychotic episode
predicts lesser degrees of depression and anxiety in acute
phase schizophrenia, may mistakenly be taken to imply
that people with schizophrenia who are not currently
psychotic would not have significant depression and
anxiety. That would be mistaken for this study should not
be generalised to non-acute phase schizophrenia. On the
contrary, previous studies suggested significant depressive
and anxiety features in schizophrenia following psychotic
episodes [31-33].
To generalise, furthermore, the study should first
be replicated at other sites, using a larger sample size.
Other factors that may influence the relationships found
in this study should be studied further. For example, our
study involved only hospitalised patients, meaning that
non-hospitalised patients should be investigated too and
compared with hospitalised patients. Furthermore, our
study excluded such potential influences as having an-
other psychiatric diagnosis in addition to schizophrenia;
a neurological condition affecting the central nervous
system; substance dependence; patients with a history of
taking benzodiazepines regularly during the past month;
and patients who received zuclo-penthixol acetate less
than 72 hours prior to applying the measures of this
study.
According to the clinical history of the longitudinal
course of the disorder available at the time of admission,
a mood episode must not have been present for a sub-
stantial portion of the total duration of the active and
residual periods of the illness – thus not meeting the
C-criterion of schizoaffective disorder [23]. Nonetheless,
it is possible that some patients in this cohort could turn
out to be suffering from schizoaffective disorder, particu-
larly where the history might not have been not suffi-
ciently telling at the time of admission, or where the
disorder was yet to unfold in a way that the C-criterion
would be met at a point after this study.
The finding that the severity of the psychotic episode
predicts the severity of anxiety should be qualified fur-
ther. That is, the anxiety measured was not in terms of
specific anxiety disorders, but in terms of general mea-
sures of anxiety features. For example, whether the se-
verity of a psychotic episode would predict the severity
of obsessions and compulsions in patients with both obses-
sive compulsive disorder and acute phase schizophrenia is
not addressed here but a question for further research.
Nonetheless, this study prompts the related question that
has not yet been thoroughly researched: does anxiety in
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of established diagnostic categories of anxiety disorders, or
may people suffer from significant anxiety symptoms in
acute phase schizophrenia even when those symptoms do
not clearly cluster into the established diagnostic categories
of anxiety disorders.
Our study suggests that the heavier burden owing to a
more severe degree of a psychotic episode is made even
heavier by more severe depressive and anxiety features
at the time. The justified clinical attention to the psych-
otic symptoms in severe degrees of acute phase schizo-
phrenia and the undoubted clinical challenges that these
symptoms pose, may overshadow if not obscure the
presence and importance of the depressive and anxiety
features. However, appreciating the burden that entails
for a specific patient is very important in an empathetic
therapeutic relationship with the patient. It is also clinic-
ally important for constructing personalised treatment
plans that account for the added burden as well as the
anticipated increased risks for suicide, self-harm, vio-
lence, treatment non-adherence, and the impulsive or
destructive behaviours associated to it [34]. Research is
required for establishing the extent of these increased
risks as well as into efficacious ways to alleviate the
compounded burden.
Conclusions
This study suggests that the severity of a psychotic epi-
sode in acute phase schizophrenia predicts the severity
of concurrent depressive and anxiety features respect-
ively. These results did not appear to be confounded by
akathisia, and prompt the question not yet researched
thoroughly as to whether clinically significant anxiety fea-
tures in acute phase schizophrenia necessarily cluster into
the established diagnostic categories of anxiety disorders.
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